Amphastar Pharmaceuticals (STU:29A) Cyclically Adjusted PS Ratio: (As of Aug. 07, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:29A Amphastar Pharmaceuticals Inc STU:29A
79 GF Score
Price €17.96
GF Value €42.35
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Amphastar Pharmaceuticals  (STU:29A) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms


Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 2.68 7.50 4.01 2.62

Amphastar Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.34 2.64 2.62 1.84 0.00

STU:29A vs ESPR, NIKA, BIOA: Cyclically Adjusted PS Ratio Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.


STU:29A
79GF Score
Amphastar Pharmaceuticals Inc STU:29A
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Amphastar Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Amphastar Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=3.609/333.9520*333.9520
=3.609

Current CPI (Jun. 2026) = 333.9520.

Amphastar Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 1.193 241.428 1.650
201612 1.183 241.432 1.636
201703 1.103 243.801 1.511
201706 1.212 244.955 1.652
201709 1.008 246.819 1.364
201712 1.035 246.524 1.402
201803 1.018 249.554 1.362
201806 1.306 251.989 1.731
201809 1.341 252.439 1.774
201812 1.704 251.233 2.265
201903 1.401 254.202 1.841
201906 1.402 256.143 1.828
201909 1.453 256.759 1.890
201912 1.524 256.974 1.981
202003 1.589 258.115 2.056
202006 1.630 257.797 2.112
202009 1.421 260.280 1.823
202012 1.586 260.474 2.033
202103 1.748 264.877 2.204
202106 1.703 271.696 2.093
202109 1.907 274.310 2.322
202112 2.137 278.802 2.560
202203 2.103 287.504 2.443
202206 2.194 296.311 2.473
202209 2.298 296.808 2.586
202212 2.465 296.797 2.774
202303 2.516 301.836 2.784
202306 2.533 305.109 2.772
202309 3.138 307.789 3.405
202312 3.081 306.746 3.354
202403 2.982 312.332 3.188
202406 3.256 314.175 3.461
202409 3.322 315.301 3.519
202412 3.472 315.605 3.674
202503 3.162 319.799 3.302
202506 3.142 322.561 3.253
202509 3.428 324.800 3.525
202512 3.315 324.054 3.416
202603 3.187 330.213 3.223
202606 3.609 333.952 3.609

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Amphastar Pharmaceuticals (STU:29A) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of €17.96 is trading 57.6% below its estimated GF Value™ of €42.35. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for STU:29A:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €42.35 vs. price of €17.96 (57.6% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the STU:29A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amphastar Pharmaceuticals Business Description

Other Exchanges AMPH:USA
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
79GF Score

Get the complete analysis for STU:29A

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.96
Price
€42.35
GF Value